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A major obstacle to the efficient production of antibody conjugates for therapy and diagnosis is the
non-ideal performance of commonly used chemicalmethods for the attachment of effector-molecules to the
antibody of interest. Here we demonstrate that this limitation can be simply addressed using 3,4-substituted
maleimides to bridge and thus functionalize disulfide bonds to generate homogeneous antibody conjugates.
This one-step conjugation reaction is fast, site-specific, quantitative and generates products with full
binding activity, good plasma stability and the desired functional properties. Furthermore, the rigid nature
of this modification by disulfide bridging enables the successful detection of antigen with a spin labeled
antibody fragment by continuous-wave electron paramagnetic resonance (cw-EPR), which we report here
for the first time. Antigen detection is concentration dependent, observable in human blood and allows the
discrimination of fragments with different binding affinity.We envisage broad potential for antibody based
in-solution diagnostic methods by EPR or ‘spinostics’.
A
substantial portion of all biotechnology products under development are antibodies and antibody frag-
ments1. Although around 30 have obtained FDA approval for therapeutic applications to date, most of
them need to be used in combination with other forms of treatment2. A major limitation is the often
insufficient clinically relevant activity of this class of proteins3,4. Conjugation of the antibody to a functional
molecule such as a cytotoxic drug for therapy or an imaging reagent for diagnosis is thus necessary and widely
applied5. The ideal chemical coupling reaction would be fast, efficient and site-specific generating a homogeneous
product which retains its antigen-binding activity. Commonly used methods do not fulfill these ideals. Lysine
modification gives rise to heterogeneousmixtures of products due to themultitude of free lysines on the surface of
antibodies and the result can be a narrow therapeutic window due to off-site toxicity6. In contrast, the introduc-
tion of an additional cysteine by genetic engineering, which is feasible even in a full antibody7, offers a point of
attachment for site-specific modification. However an unpaired cysteine can have a detrimental effect on the
production yield8 and usually results in the formation of dimers and mixed disulfides, which have to be carefully
reduced before chemical coupling7. As an alternative non-natural amino acids can be used as unique chemical
handles but their successful insertion is laborious and context-dependent9 and the performance of the available
chemical toolbox for their modification is non-ideal10. To avoid the need for genetic engineering and obtain some
site-specificity the inter-chain disulfide bonds of antibodies can be reduced, followed by reaction of the revealed
cysteines with thiol-specific chemistry11. Yet the cleavage of cystines can have negative effects on the stability12 and
effector-functions of antibodies13. A promising solution to these problems is the utilization of bis-reactive
bridging reagents that are able to restore a covalent linkage between the two cysteines14,15.
We have recently described a new strategy for such ‘‘functionalisation by bridging’’ of disulfide bonds16–18.
Substitution of the 3- and 4-positions of the widely used maleimide-motif with good leaving groups yields
reagents that react rapidly and efficiently with a reduced cystine, inserting a rigid two-carbon bridge without
the introduction of new chiral centers. By careful choice of the leaving groups we have synthesized reagents that
can be used in tandem with reducing agents, enabling an in situ protocol in which the functionalized disulfide
bonds are formed in minutes. Furthermore, the nitrogen in the maleimide ring is readily modified synthetically
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and various functional groups can be attached at this position, allow-
ing diverse modification of proteins. We envisage that our methodo-
logy could be used to prepare a new generation of functionalized
antibody analogues. In addition we were attracted to the possibility
that the rigidity of the maleimide bridge would couple the tumbling
motions of an antibody tightly to those of an attached spin label19 and
thus allow the assembly of immuno-biosensors for EPR-based detec-
tion of antibody-antigen interactions or ‘spinostics’ (Fig. 1). This
approach would have numerous advantages over other methods
for monitoring such interactions, the most prominent being its
direct, and theoretically understood, connection to the molecular
immobilization characteristic of binding.
Results
Site-specific bridging of an antibody fragment disulfide bond. To
test the ideas discussed above, we decided to work with a variable
fragment (Fv), the smallest portion of an antibody which retains full
binding activity. We chose a carcinoembryonic antigen (CEA)
specific single-chain Fv fragment (scFv) shMFE20, in which the
inter domain linker (Gly4Ser)3 had been changed to (Gly4Ser)4 to
increase the monomer to dimer ratio in the production process
(Supplementary Fig. S1). A disulfide bond had been engineered to
further stabilize the monomeric form of the construct21 by
performing two amino acid substitutions: Gly to Cys and Ala to
Cys at Kabat positions H44 and L100 respectively, resulting in a
unique cystine-stabilized single-chain Fv fragment (sscFv). The
location of the artificial cystine corresponds to that identified as a
general site within the scFv framework to stabilize Fvs by disulfide
bonds22,23.
To modify the accessible disulfide bond we initially used a sequen-
tial protocol16: reduction of the cystine with dithiothreitol (DTT, 20
equivalents towards the antibody concentration), followed by addi-
tion of an excess of dibromomaleimide (30 equiv). Full conversion to
the maleimide-bridged sscFv (Fig. 2a) was observed by LC-MS in less
than 5 min. Analysis of the product revealed a small amount of higher
molecular weight species (Fig. 2b and Supplementary Fig. S2) which
did not appear to be formed by maleimide cross-linking as they were
stable to the addition of more DTT16 (data not shown). In order to
avoid this apparent multimer formation, we established the condi-
tions for an in situ modification17. As the disulfide bond of the
CEA-specific sscFv was relatively resistant to reduction by tris
(carboxyethyl)phosphine (TCEP, Supplementary Methods) a mix of
dithiophenolmaleimide and benzeneselenol (15 equiv each) was
employed to reach full conversion (Supplementary Fig. S3). The speed
of the reaction was not affected (Fig. 2c) and no higher molecular
weight products were detectable (Fig. 2b and Supplementary Fig. S2),
illustrating that the in situ protocol avoids the common issue of
undesired scFv multimerisation24. During optimization we found that
as little as 2 equiv of bridging-reagent were sufficient to yield the
completely modified sscFv when two portions of the reducing agent
were added or its quantity increased to 25 equiv (Supplementary
Fig. S4).
When we compared the biological activity of sequentially and in
situ bridged sscFv analogues with the unmodified antibody by ELISA
we found that the binding activity was not merely retained but actu-
ally increased (Fig. 2d). This result was confirmed by surface plas-
mon resonance (SPR) measurements (Kd unmod 20.8 6 2.9 nM,
Kd bridged 6.4 6 0.3 nM). Although the residues which had been
replaced by cysteines are in the ideal position for the introduction
of a disulfide bond23, its presence or geometry had possibly intro-
duced structural strain into the sscFv which is released upon inser-
tion of the maleimide-bridge. The likewise enhanced activity of an
alkylated analogue, in which both cysteines had been reacted sepa-
rately with maleimide and thus had lost the disulfide bridge comple-
tely, supports this possibility (Fig. 2e).
Functionalisation of the sscFv disulfide bond.CEA is a cell-surface
glycoprotein (,200 kDa), which is overexpressed in a wide range of
cancers and its blood-concentration is used as a clinical marker for
post-surgical monitoring of primary colon carcinomas25. To equip
the CEA-specific sscFv with imaging properties we conjugated the
protein via the maleimide bridge to fluorescein, biotin and two types
of nitroxide spin label. We also attached a polyethylene glycol (PEG)
chain (5 kDa) as a simple model for PEGylation, a widely used
process to increase the circulation time and half-life of antibody
fragments26. All N-functionalized maleimides were synthesized
following published protocols16,17,27 with the exception of the spin
labels, for which we developed a milder one-step method of
attachment to the bridging moiety (Supplementary Fig. S5 and
Supplementary Methods).
The functionalisation of the sscFv via the sequential (fluorescein
and biotin) or in situ protocol (spin labels and PEG) was as fast and
efficient as observed for the bridging reaction with unmodified mal-
eimides (Supplementary Fig. S6) and simple purification via a desalt-
ing column or in the case of PEGylation by nickel magnetic beads via
its C-terminal his6-tag, furnished the homogeneously modified ana-
logues in 80–90% yields. All analogues exhibited an increased activity
as found for the bridged sscFv by ELISA (Fig. 2e,f) and also by SPR in
the case of the PEG-sscFv (Kd PEGylated 8.7 6 0.3 nM).
Having shown previously that an excess of thiols can cleave the
maleimide fromwithin a disulfide bond16 we tested the stability of the
bridged sscFv alongside controls in human plasma, which typically
contains about 18 mM of free thiol28. Relatively constant amounts of
Figure 1 | Concept of disulfide bond-based antibody functionalisation and EPR-sensing of the antibody-antigen interaction (‘spinostics’). Cartoons
are derived from a published model of MFE2344.
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the sscFv analogue could be isolated from these samples over the time
of the experiment (Fig. 2g) and the LC-MS spectra of this material
showed no loss of the maleimide bridge (Supplementary Fig. S7).
Notably, subjecting the modified antibody fragment to cytoplasmic
concentrations of glutathione or other reducing agents (7 mM) in
buffer led to the formation of un-bridged sscFv over time (Fig. 2h),
implying a potential cargo-release mechanism under in vivo condi-
tions. In addition bridging via the cystine helped to preserve the
activity of the sscFv during incubation at 37uC, as did the alkylation
of the cysteines (Fig. 2i), suggesting a role of the disulfide bond, once
reduced, in the loss of antibody functionality.
To compare our method with the traditional method of conjuga-
tion via lysine residues, we carried out amine-based PEGylation of
the sscFv with 5 kDa PEG chains activated by an N-hydroxysucci-
nimide ester (NHS) group. This reaction produced under varying
conditions the typical mix of differentially conjugated antibodies
(Fig. 3a) compared to a single product obtained by functional
bridging of the disulfide bond (Fig. 3b). The mono-PEG-sscFv and
a multi-PEG-sscFv species prepared with NHS-chemistry were puri-
fied (yields of 14% and 28% respectively) and their binding capacity
tested by ELISA, which clearly showed the superiority of a defined
and site-specific approach (Fig. 3c).
The other analogues were evaluated with regard to their signaling
properties: dilution series of CEA-expressing and non-expressing
cell lines were settled in 96-well plates treated with the fluorescein-
sscFv and analyzed with a simple ELISA reader. The signal intensity
Figure 2 | Synthesis, activity and stability of CEA-specific sscFv analogues. (a) Deconvoluted LC-MS spectra of unmodified and maleimide-bridged
sscFv (requires 26,836 Da). Conditions a) (sequential): 20 equiv DTT for 1 h, then 30 equiv of dibromomaleimide; conditions b) (in situ): 15 equiv
dithiophenolmaleimide and 15 equiv benzeneselenol; conditions c) (in situ): 2 equiv dithiophenolmaleimide and 25 equiv benzeneselenol. The
additional peaks are disulfide bond containing impurities in the starting material. (b) SDS-PAGE of sequentially and in situ bridged sscFv. Processed
antibody was treated with maleimides but no reducing agent. (c) Timed LC-MS data of the in situ bridging reaction of sscFv. The signal refers to the
relative abundance of themass ion of bridged sscFv. (d) ELISA of variably bridged sscFv against full length CEA. (e) ELISA of alkylated and functionalized
sscFv against full length CEA. (f) ELISA of functionalized sscFv against full length CEA. (g) SDS-PAGE of bridged sscFv isolated from human plasma after
incubation at 37uC and loading controls. Unmodified and alkylated sscFv were treated for 7 d and isolated. The negative control contained no antibody.
(h) Stability of the bridged sscFv against a 1003 excess of thiols as determined by LC-MS. The signal refers to the relative abundance of themass ion of the
un-bridged sscFv. (i) Normalized activity of the sscFv and its analogues after incubation in human plasma at 37uC as determined by ELISA against full
length CEA. Full-length gels are presented in Supplementary Figure S16. ELISAs d–f and i were performed in triplicates; error bars show s.d.
www.nature.com/scientificreports
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had good correspondence to the number of cells present (Fig. 3d)
and the detection of as few as about 8,000 cells was possible. The
biotin-sscFv analogue was coupled to horseradish peroxidase (HRP)
by mixing with a commercially available streptavidin-conjugate
(HRP-Strep) of the enzyme. This could be done either directly in
the wells of an ELISA plate, after pre-incubation of the biotiny-
lated antibody with the antigen, or in solution from which the
final HRP-sscFv could be purified (Supplementary Fig. S8). Both
antibody-enzyme conjugates produced a specific and strong signal
in two- or one-step ELISAs (Fig. 3e,f and Supplementary Fig. S9).
‘Spinostics’ – EPR-based immuno-sensing. To explore the idea of
‘spinostics’ we conjugated two dithiophenolmaleimide-coupled
nitroxide spin labels to the sscFv. They differ in that the PROXYL
radical is connected either directly to the maleimide ring, yielding
dithiophenolmaleimide-N-PROXYL (TPMP, Fig. 4a and Supple-
mentary Methods) or with an additional carbon in the linkage
(TPMCP, Fig. 4b and Supplementary Methods). Direct comparison
of cw-EPR spectra of the free label and the spin labeled sscFv
analogues confirmed successful conjugation to the antibody
(Fig. 4a,b, blue lines). The antibody fragment labeled with TPMP
Figure 3 | Functionality of the CEA-specific sscFv analogues. (a) SDS-PAGE of variously NHS-based PEGylated sscFv. The reaction was quenched after
indicated times with an excess of glycine. (b) SDS-PAGE of maleimide-based PEGylated sscFv. Processed antibody was treated with PEGylation reagent
but no reducing agent. (c) ELISA of purifiedmaleimide- andNHS-based PEGylated sscFv against full length CEA. (d) Fluorescence read-out of a dilution
series of CEA expressing (CAPAN-1) and non-expressing (A375) cancer cell lines after treatment with fluorescein-sscFv (ex. 488 nm; em. 518 nm).
(e) Comparison of the ELISA-activity of commonly formed reporter complexes (secondary antibody conjugated to HRP) with on-plate formation by
addition of HRP-Strep conjugate to antigen-bound (full length CEA) biotin-sscFv. In the 1:4600 dilution of the HRP-Strep conjugate no non-specific
background was observed. (f) One-step ELISA of preformed and purified HRP-sscFv conjugate against full length CEA. Experiments (c–f) were
performed in triplicates; error bars show s.d.
www.nature.com/scientificreports
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Figure 4 | EPR-based monitoring of antibody-antigen interactions. (a) From top to bottom: TPMP molecule, free TPMP normalized EPR spectrum
(black), MP-sscFv (blue, 10 mM) and NA1-bound state (red, 70 mMNA1) EPR spectra in human blood, MP-sscFv (blue, 250 nM) and NA1-bound state
(red, 1.75 mMNA1) EPR spectra in human blood, MP-sscFv (blue, 100 nM) and NA1-bound state (red, 400 nM NA1) EPR spectra in human blood. (b)
Same as (a) but for MCP-sscFv. (c) 10 mMMP-sscFv and (d) MCP-sscFv binding curves. NA1 concentrations are 0, 3, 6, 9, 12, 15, 20, 22.5, 25, 30, 35, 40,
45, 50, 60 and 70 mM. Red circles (PBS), squares (human plasma), triangles (whole human blood) represent the respective raw data points and red lines
represent best fits for raw data. Blue shapes and lines represent data points for simulations and fits of simulated data, respectively. (e) 250 nM binding
curves for MP-sscFv and (f) MCP-sscFv with NA1 (circles) and full length CEA (squares), respectively. Fits are as described for c and d. NA1 and full length
CEA concentrations are 0, 25, 50, 75, 100, 125, 187.5, 250, 375, 500, 625, 750, 875, 1000, 1250, 1500 and 1750 nM (calculated and simulated Kd values are
listed in Supplementary Table S1). (g) MP-sscFv (blue, open circles) and MP-sscFv-SM3E (red, open circles) thermal stability shift assay with (closed
circles) and without NA1 (70 mM) present. Tm values were fit using Supplementary Equation S2. (h) Same as g but for MCP-sscFv and MCP-sscFv-SM3E.
Tm shifts are mentioned in the main text and all other values and enthalpies of unfolding are listed in Supplementary Table S2. Raw data represent the ratio
of the low field and central nitroxide peaks. Error bars shown represent the 95% confidence boundaries as calculated from the data fitting process.
www.nature.com/scientificreports
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(MP-sscFv) exhibited a more immobile nitroxide spectrum, as
indicated by its broader spectral components, in comparison to the
fragment labeled with TPMCP (MCP-sscFv).
Upon addition of antigen to the spin labeled sscFv analogues in the
form of NA1, a 26 kDa N-terminal fragment of CEA, substantial
changes in the EPR spectra were observed (Fig. 4a,b, red lines) in
contrast to control experiments with BSA (Supplementary Fig. S10).
To our knowledge, successful monitoring of such a binding event
with EPR has not been reported before for a spin label attached to an
antibody29. Similar effects were found in human plasma and also in
whole blood (Supplementary Fig. S11) where the signal was surpris-
ingly stable despite the presence of the natural reducing agent ascor-
bate30.We generated saturation binding curves in these media as well
as in PBS, using the mean squared deviation (m.s.d.) of NA1 bound
spectra from the unbound spectrum (Fig. 4c,d and Supplementary
Fig. S11). The multi-component EPR spectra were also simulated
and relative weightings of each of the two components accounting
for approximately 95% of the spectra were extracted to monitor
binding. The simulated data typically had r.m.s.d errors of , 0.06.
Fitting (Supplementary Equation S1) of MP-sscFv binding curves,
obtained at 10 mM antibody concentration, yielded Kd values of: 1.91
6 0.78 mM, 4.35 6 1.27 mM and 6.46 6 1.7 mM in PBS, plasma and
whole blood, respectively for raw data; compared to: 1.22 6 0.60 mM,
3.94 6 2.06 mM and 5.63 6 2.06 mM for data analyzed using the
simulations. As expected, binding affinities are reduced as the binding
matrix becomes more complex as in blood31. In contrast, when
working with MCP-sscFv, the antibody concentration was constantly
overestimated in comparison to its experimental value during the
fitting procedure and generally predicted lower affinity values
(Supplementary Table S1). The higher Kd values could be explained
by the uncoupling of the binding event from the spin label reporting
the protein-protein interaction, facilitated by the extra carbon atom32.
This emphasizes the high degree of immobilization that is achieved by
attachment of the spin label into a rigid disulfide bridge. Furthermore,
by adding 30% wt/vol sucrose to both spin labeled sscFv analogues
about 80% of spectral changes encountered could be replicated
through the additional viscosity (Supplementary Fig. S12). These
spectra illustrate the dominance of protein tumbling rates33 on
sscFv EPR spectra upon binding for both labels and once again aid
in proving the importance of the rigidity of the label insertion.
To simulate conditions closer to the realities of clinical settings we
repeated the binding study with NA1 as well as full length CEA
purified from human colon carcinomas at lower sscFv concentra-
tions. Data – which could be successfully simulated – were acquired
at antibody concentrations as low as 250 nM with a good signal to
noise ratio (Fig. 4e,f and Supplementary Fig. S13). To demonstrate
the potential to work at even lower concentrations we recorded spec-
tra of bound and unbound MP- and MCP-sscFv at 100 nM respect-
ively (Fig. 4a,b). Although relatively noisy, spectral differences that
resemble those observed at higher concentrations are visible and
most prominent at the low field peaks.
To further explore the utility of the ‘spinostics’ platform, we inves-
tigated its application as an antibody fragment-based thermal
stability shift assay (TSSA) with both labels. Here, the presence of
a saturating NA1 concentration on the thermal stability of the sscFv
was monitored as a function of increasing temperature. As expected,
the Gibbs free energy of unfolding of the labeled sscFv was enhanced
in the presence of antigen, resulting in a shift in the melting temper-
ature (Tm) of the antibody fragment of 8.6 6 2.7 K and 7.3 6 1.8 K
for MP- and MCP-sscFv, respectively (Fig. 4g,h, blue traces and
Supplementary Fig. S14). We performed a similar experiment on
sscFv-SM3E, an affinity matured variant of the CEA-specific
sscFv20. sscFv-SM3E showed a further Tm shift of 13.1 6 2.9 K and
13.8 6 2.4 K for MP- and MCP-sscFv-SM3E, respectively (Fig. 4g,h,
red traces). These values correlate well with first derivative plots of
the fits (Supplementary Fig. S15).
Discussion
We were able to show that next generation maleimides allow the
assembly of a range of fully active homogenous antibody conjugates
in high yields and with the desired functional properties. The simple,
efficient and site-specific chemistry, the plasma stability of the mal-
eimide bridge and its potential in controllable in-cell cleavage27,34
eliminates many disadvantages of currently used conjugation chem-
istry and drawbacks of arduous antibody-engineering. The versatility
of this chemical platform also facilitates the presented ‘spinostics’
technology. Themix andmeasure metrology employed here for both
the saturation binding curve generation and the TSSA demonstrates
their potential for automation and high throughput applicability.
TSSA lends itself particularly well as a complementary tool to current
methods employed in screening antibody-antigen interactions,
including various ligands, drug compounds and environmental tar-
gets35, with great potential for stability screening of antibody frag-
ments. Furthermore, the matrix insensitive nature of EPR makes it
attractive for ligand screening under physiological conditions, with
minimal sample pre-treatment necessary.
Currently, our lower limit of detection, found in this proof-of-
concept experiment using a standard commercial EPR spectrometer
(Bruker EMXplus) is 100 nM.We anticipate that two to three orders
of magnitude sensitivity gains would make this a clinically relevant
CEA assay36. An order of magnitude in sensitivity is potentially feas-
ible with current technologies for example through the use of
improved resonators37 or rapid scan EPR38, which has future promise
of decreased scan times and increased signal to noise over conven-
tional cw-EPR. Additionally, our experiments will motivate similar
work on biomarkers for other diseases and acute phase proteins with
higher concentrations (e.g. C-reactive protein39), which could be de-
tected readily with current generation EPR spectrometers. Unlike
many biosensor and bio-interaction technologies, the ‘spinostics’
platform described here does not require a surface and therefore is
not prone to the gross overestimation of Kd typical for surface-based
probes31, does not require complex surface immobilization chemis-
tries and avoids related heterogeneity problems. Moreover, com-
pared to conventional optical technologies, solution binding can be
observed in opaque matrixes such as blood, lending itself well to
point-of-care diagnostics and EPR spectra can be readily simulated
to obtain more detailed information about the systems dynamics.
In conclusion, the combination of a powerful new chemical
approach to site-specific antibody conjugation with an EPR-based
detection method offers a platform for the development of new tools
to study biological systems and for application in diagnostics and
biotechnology.
Methods
Protein synthesis.We produced the sscFv variant of shMFE and of the high affinity
shMFE variant SM3E using the methanol inducible Pichia pastoris production
platform. In brief, a DNA fragment encoding shMFE or SM3E20 was synthesized
(Genescript USA Inc.) and relative to the original sequence the following changes
introduced: two substitutions at Gly’H44’Cys as well as Ala’L100’Cys (Kabat
numbering), the linker was extended from (Gly4Ser)3 to (Gly4Ser)4 and sequences
encoding KREAEA and His6 plus stop codon were added to the 5 and 3 prime,
respectively. The sequence was digested with EcoRI and NotI, and ligated into a
pPICZa´B vector (Invitrogen). After amplification in E. coli TOP10 (NEB) the
construct was linearized with PmeI and transferred by electroporation into Pichia
pastoris X33 (Invitrogen). We used the transformant with the highest protein
expression for protein production by fermentation with initial purification using
radial bed adsorption IMAC as published40,41. The IMAC fraction containing the
protein was concentrated with a Labscale TFF system (Millipore) using a Biomax
10 kDa ultrafiltration module and subsequently applied to a Superdex 75 size-
exclusion column (500 ml bed volume, GE Healthcare) which was equilibrated with
PBS (pH 7.4). The fraction containing themonomer sscFv was collected and stored at
280uC. The protein material was . 95% pure as estimated by SDS-PAGE.
We synthesized and purified the NA1 fragment of CEA as described elsewhere42.
Bridging of the sscFv. A solution of the CEA-specific sscFv in PBS (pH 7.4) was
diluted in the same buffer and dimethylformamide (DMF, 10% vol/vol final amount)
to yield a concentration of 70.0 mM (1.87 mg ml21) prior to experimentation. All
maleimides and benzeneselenol were prepared in DMF as highly concentrated stock
www.nature.com/scientificreports
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solutions, while DTT was dissolved in PBS. We established three protocols:
a) Sequential bridging: the antibody fragment was treated with 20 equiv DTT for 1 h
at ambient temperature, then 30 equiv of dibromomaleimide were added for 10 min.
b) In situ bridging: 15 equiv of dithiophenolmaleimide were added to the antibody
solution followed by 15 equiv of benzeneselenol. The mixture was incubated for
20 min at ambient temperature. c) In situ bridging (alternative): 2 equiv of
dithiophenolmaleimide were added to the antibody solution followed by 25 equiv of
benzeneselenol. The mixture was incubated for 20 min at ambient temperature.
Successful modification was confirmed by LC-MS. Timed data was obtained by
incubation of the reaction mixtures for 60 min and withdrawing and analyzing
aliquots at various time points.
Functionalisation of the sscFv. We prepared all maleimides as highly concentrated
stock solutions in DMF with the exception of N-PEG5000-dithiophenolmaleimide,
which was prepared in PBS. The sscFv was conjugated to biotin- and fluorescein-
dibromomaleimide via protocol a) and to the nitroxide spin labels as well as the PEG
chain via protocol b) or c). Efficient formation of all analogues was verified by LC-MS
(and SDS-PAGE in the case of PEGylated sscFv). Functionalized antibody fragments
were purified with PD MiniTrap G-25 desalting columns (GE Healthcare) or
PureProteome Nickel Magnetic Beads (Millipore) following manufacturers’
instructions. Concentrations were determined by UV/Vis using a calculated
molecular extinction coefficient of e280 5 48,735 M21 cm21.
Antigen binding of the CEA-specific sscFv monitored by EPR. The concentration
of spin labeled CEA-specific sscFv was held constant at 10 mM or 250 nM and the
antigen concentration was varied between 0–70 mM for experiments at 10 mM and
0–1.75 mM at 250 nM. For 10 mM data, the final volumes were normalized to 15 mL
with PBS. Experiments with whole human blood and human plasma were conducted
under the same conditions as PBS and constituted 10 mL of the entire volume.
Therefore, the only variable was the antigen in all cases. All samples were incubated
for 30 min at 37uC under constant agitation. Samples were then transferred into
flame sealed 1 mm (inner diameter) capillaries and briefly centrifuged. Loaded
capillaries were placed into a pre-warmed (37uC) 4102ST resonator controlled by a
Bruker ER4111VT temperature control unit that had been pre-calibrated with an
external thermocouple. A Bruker EMXplus continuous-wave spectrometer operating
at 9–10 GHz (X-band) was used as microwave source and detector. Data were
recorded using the Bruker Xenon software at 63.25 mW microwave power, 70 dB
gain, 2G modulation amplitude, 100 kHz modulation frequency and a typical scan
time of 25–30 s. 36 scans were recorded for each spectrum using the 4102ST cavity.
The same conditions were applied for the data collection at 250 nM antigen
concentration with following exceptions: the number of scans was 100, sample
volumes were 200 mL, microwave power was 126.2 mW and a quartz flat-cell was
used as a sample holder in combination with a 4122SHQE resonator. No saturation
broadening was detected when comparing low and high concentration EPR spectra.
Spectra at 100 nM were acquired similarly to 250 nM data but were a total of
200 scans each. Sample holder and resonator were orientated horizontally to
minimize sinking of red blood cells. The flat-cell was washed with concentrated nitric
acid and ethanol between measurements. We acquired the data in random order to
maintain fair testing conditions and further minimize non-specific adsorption to the
flat-cell. Simulations of nitroxide EPR spectra were performed using the MATLAB
plug-in Easyspin43 (v4.0.0).
Thermal stability shift assay with CEA-specific sscFv and sscFv-SM3E. The spin
labelled CEA-specific sscFv or sscFv-SM3E (10 mM) alone or in its bound form
(70 mM NA1) were heated within a 4102ST cavity containing an evacuated quartz
dewar. Sampling temperatures were collected on heating at 293, 298, 303, 308, 313,
318, 323, 325, 327, 329, 331, 333, 335, 338, 340, 343, 345 and 348 K. A constant
nitrogen gas flow was supplied at the desired temperature using a Bruker ER4111VT
temperature control. The temperature offset was calibrated using an external
thermocouple prior tomeasuring. Measuring volumes were 10 mL andwere placed in
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